<?xml version="1.0" encoding="utf-8"?>
<search>
  
  
  
  <entry>
    <title>About ChenLab</title>
    <link href="/2025/06/19/ChenLab%E7%AE%80%E4%BB%8B/"/>
    <url>/2025/06/19/ChenLab%E7%AE%80%E4%BB%8B/</url>
    
    <content type="html"><![CDATA[<h4 id="ç ”ç©¶æ–¹å‘"><a href="#ç ”ç©¶æ–¹å‘" class="headerlink" title="ç ”ç©¶æ–¹å‘"></a>ç ”ç©¶æ–¹å‘</h4><p>å‘¼å¸é“ç—…æ¯’æ„ŸæŸ“å…ç–«åº”ç­”åŠæ–°å‹ç–«è‹—ç ”ç©¶</p><ol><li><p>å¹¿è°±æµæ„Ÿç–«è‹—çš„ç ”å‘</p></li><li><p>å¹¿è°±æ–°å† é»è†œç–«è‹—çš„ç ”å‘</p></li><li><p>æ²»ç–—æ€§äººå•æŠ—çš„ç ”å‘å’Œä¸´åºŠåº”ç”¨ </p></li><li><p>Bç»†èƒå…ç–«åº”ç­”æœºåˆ¶åŠBCRå…ç–«ç»„åº“ç ”ç©¶</p></li></ol><h4 id="å·¥ä½œç»å†"><a href="#å·¥ä½œç»å†" class="headerlink" title="å·¥ä½œç»å†"></a>å·¥ä½œç»å†</h4><p>2018/10-è‡³ä»Š    ä¸­å±±å¤§å­¦å…¬å…±å«ç”Ÿå­¦é™¢ï¼ˆæ·±åœ³ï¼‰ï¼Œæ•™æˆ</p><p>2017/06-2018/09  èŠåŠ å“¥å¤§å­¦åŒ»å­¦é™¢ï¼Œç ”ç©¶ä¸“å‘˜   </p><p>2013/06-2017/05  èŠåŠ å“¥å¤§å­¦åŒ»å­¦é™¢ï¼Œåšå£«å</p><p>2012/09-2013/05  æ˜å°¼è‹è¾¾å·ç«‹å¤§å­¦è¯å­¦é™¢ï¼Œåšå£«å</p><h4 id="æ•™è‚²ç»å†"><a href="#æ•™è‚²ç»å†" class="headerlink" title="æ•™è‚²ç»å†"></a>æ•™è‚²ç»å†</h4><p>2006/09-2012/05  æ­¦æ±‰å¤§å­¦/ä¸­å›½ç§‘å­¦é™¢æ­¦æ±‰ç—…æ¯’ç ”ç©¶æ‰€ï¼Œå¾®ç”Ÿç‰©ï¼Œç†å­¦åšå£«</p><p>2002/09-2006/07  æ­¦æ±‰å¤§å­¦ï¼Œç”Ÿç‰©æŠ€æœ¯åŸºåœ°ç­ï¼Œç†å­¦å­¦å£«</p><h4 id="ä¸ªäººç®€ä»‹"><a href="#ä¸ªäººç®€ä»‹" class="headerlink" title="ä¸ªäººç®€ä»‹"></a>ä¸ªäººç®€ä»‹</h4><p>é™ˆè€€åº†ï¼Œ ä¸­å±±å¤§å­¦å…¬å…±å«ç”Ÿå­¦é™¢ï¼ˆæ·±åœ³ï¼‰ï¼Œæ•™æˆï¼Œåšå£«ç”Ÿå¯¼å¸ˆã€‚â€œæµ·å¤–é«˜å±‚æ¬¡å¼•è¿›äººæ‰è®¡åˆ’â€é’å¹´é¡¹ç›®è·å¾—è€…ã€æ·±åœ³å¸‚æ°å‡ºé’å¹´é¡¹ç›®è·å¾—è€…ã€ä¸­å±±å¤§å­¦â€œç™¾äººè®¡åˆ’â€ä¸­é’å¹´æ°å‡ºäººæ‰ã€ä¸­å±±å¤§å­¦â€œé€¸ä»™å­¦è€…è®¡åˆ’â€ä¼˜ç§€å­¦è€…ï¼Œæ‹…ä»»ä¸­å›½ç–«è‹—è¡Œä¸šåä¼šç–«è‹—åŸºç¡€ç ”ç©¶ä¸“ä¸šä¼šå‰¯ä¸»ä»»å§”å‘˜ï¼Œå›½å®¶è¯å“ç›‘ç£ç®¡ç†å±€ç–«è‹—åŠç”Ÿç‰©åˆ¶å“è´¨é‡ç›‘æµ‹ä¸è¯„ä»·é‡ç‚¹å®éªŒå®¤é¡¾é—®ä¸“å®¶ï¼Œæ·±åœ³å¸‚å…ç–«åä¼šå‰¯ç†äº‹é•¿ã€‚å·²åœ¨Cellï¼ŒSignal Transduction and Targeted Therapyï¼ŒNature Communicationsï¼ŒCellular &amp; Molecular Immunologyï¼ŒEmerging Microbes &amp; Infectionsï¼ŒPLOS Pathogensï¼ŒJournal of Virology,ç­‰ä¸€æµæœŸåˆŠä¸Šå‘è¡¨å¤šé¡¹é‡è¦æˆæœã€‚æˆ‘ä»¬ç‡å…ˆæå‡ºäº†ç¥ç»æ°¨é…¸é…¶æ˜¯æµæ„Ÿå¹¿è°±ç–«è‹—çš„å€™é€‰å…ç–«åŸçš„ç§‘å­¦è§‚ç‚¹ï¼Œå¹¶åŸºäºæŠ—åŸå†³å®šç°‡ä¿¡æ¯è®¾è®¡äº†ç›¸åº”çš„æ ¸é…¸ç–«è‹—ï¼ŒåŒæ—¶å¼€å‘äº†å¯é˜²æ–°å† ä¼ æ’­çš„æ–°å‹æ–°å† é»è†œç–«è‹—ï¼Œå¹¶å¼€å±•äº†ç ”ç©¶è€…å‘èµ·çš„ä¸´åºŠå®éªŒã€‚ä¸»æŒåŒ…æ‹¬å›½å®¶ç§‘æŠ€éƒ¨é‡ç‚¹ç ”å‘è®¡åˆ’è¯¾é¢˜é¡¹ç›®ï¼Œå›½å®¶è‡ªç„¶åŸºé‡‘å§”é‡å¤§ç ”å‘è®¡åˆ’åŸ¹è‚²é¡¹ç›®ï¼Œå›½å®¶è‡ªç„¶åŸºé‡‘å§”é¢ä¸Šé¡¹ç›®ï¼Œå¹¿ä¸œçœé‡ç‚¹ç ”å‘é¡¹ç›®ï¼Œæ·±åœ³å¸‚é‡ç‚¹ç ”å‘é¡¹ç›®ï¼Œæ·±åœ³å¸‚æ°å‡ºé’å¹´é¡¹ç›®ï¼Œä¸­å±±å¤§å­¦é’å¹´æ•™å¸ˆé‡ç‚¹åŸ¹è‚²é¡¹ç›®ç­‰å¤šä¸ªå›½å®¶çœå¸‚é¡¹ç›®æ”¯æŒ</p><h4 id="ç ”ç©¶ç®€ä»‹"><a href="#ç ”ç©¶ç®€ä»‹" class="headerlink" title="ç ”ç©¶ç®€ä»‹"></a>ç ”ç©¶ç®€ä»‹</h4><p>æµæ„Ÿç—…æ¯’ã€æ–°å† ç—…æ¯’ç­‰å‘¼å¸é“ç—…æ¯’çš„æŒç»­å˜å¼‚ï¼Œå¯¹å…¨çƒå…¬å…±å«ç”Ÿæ„æˆä¸¥å³»æŒ‘æˆ˜ã€‚ç–«è‹—æ˜¯é˜²æ§ä¼ æŸ“ç—…æœ€å…·æˆæœ¬æ•ˆç›Šçš„å…³é”®æ‰‹æ®µï¼Œä½†å…¶ä¿æŠ¤æ•ˆæœå¸¸å› ç—…æ¯’å¿«é€Ÿå˜å¼‚è€Œå‡å¼±ï¼ˆå¦‚æµæ„Ÿç–«è‹—è¿‘20å¹´å¹³å‡ä¿æŠ¤ç‡ä»…çº¦40%ï¼Œè™½ç„¶å…¶åœ¨2024å¹´æµæ„Ÿç–«è‹—çš„é”€å”®é¢æ¥è¿‘90äº¿ç¾é‡‘ï¼‰ã€‚å› æ­¤ï¼Œå¼€å‘èƒ½æœ‰æ•ˆåº”å¯¹ç—…æ¯’å˜å¼‚ã€æä¾›æ›´å¹¿æ³›å’ŒæŒä¹…ä¿æŠ¤çš„**<em>â€œå¹¿è°±ç–«è‹—â€**</em>ï¼Œæˆä¸ºè§£å†³è¿™ä¸€å…¨çƒæ€§æŒ‘æˆ˜çš„æ ¸å¿ƒçªç ´å£å’Œå›½é™…å‰æ²¿ç„¦ç‚¹ã€‚å¹¿è°±ç–«è‹—çš„ç ”å‘çš„çªç ´ç‚¹åœ¨äºç²¾å‡†é¶å‘ç—…æ¯’ä¿å®ˆè¡¨ä½åŠå…ç–«åº”ç­”æœºåˆ¶ï¼Œå®ç°å¯¹å¤šäºšå‹ã€è·¨å®¿ä¸»åŠæ–°å‹å˜å¼‚æ ªçš„äº¤å‰ä¿æŠ¤ï¼Œè¿™ä¸€ç‰¹å¾ä½¿å…¶æˆä¸ºå›½é™…ç–«è‹—é¢†åŸŸçš„å‰æ²¿æ”»å…³æ–¹å‘ã€‚</p><p>åœ¨æµæ„Ÿé¢†åŸŸï¼Œæˆ‘ä»¬ç‡å…ˆæå‡ºäº†ç¥ç»æ°¨é…¸é…¶æ˜¯æœªæ¥å¹¿è°±å€™é€‰å…ç–«åŸçš„ç§‘å­¦è§‚ç‚¹ï¼Œçªç ´äº†ä¼ ç»Ÿä»…èšç„¦è¡€å‡ç´ ï¼ˆHAï¼‰çš„å±€é™ã€‚æˆ‘ä»¬å»ºç«‹äº†é’ˆå¯¹ç¥ç»æ°¨é…¸é…¶ï¼ˆNAï¼‰è›‹ç™½çš„é«˜é€šé‡äººæºå•å…‹éš†æŠ—ä½“ç­›é€‰å¹³å°ã€‚é¦–æ¬¡æˆåŠŸè·å¾—å¹¶ç³»ç»Ÿé‰´å®šäº†ä¸€ç³»åˆ—äººæºNAç‰¹å¼‚æ€§å•æŠ—ï¼Œè¯å®å®ƒä»¬å…·æœ‰å¹¿è°±æŠ‘åˆ¶ä¸åŒäºšå‹æµæ„Ÿç—…æ¯’å¤åˆ¶çš„èƒ½åŠ›ï¼Œé¢ è¦†äº†â€˜NAæŠ—ä½“æ— ä¿æŠ¤ä½œç”¨â€™çš„ä¼ ç»Ÿè®¤çŸ¥ï¼Œæ˜¾è‘—æå‡äº†å­¦ç•Œå¯¹NAå…ç–«åŸåŠŸèƒ½çš„ç†è§£ (Cell, 2018; J Virol, 2019)ã€‚è¿›ä¸€æ­¥ï¼Œæˆ‘ä»¬ç²¾å‡†é‰´å®šäº†è¿™äº›å¹¿è°±NAæŠ—ä½“çš„å…³é”®ä½œç”¨é¶ç‚¹ï¼ˆæŠ—åŸè¡¨ä½ï¼‰ (Nat Commun, 2025)ã€‚åŸºäºè¿™äº›å‘ç°ï¼Œæˆ‘ä»¬åˆ©ç”¨åå‘ç–«è‹—å­¦åŠAlphaFoldé¢„æµ‹å…³é”®ç»“æ„ï¼ŒæˆåŠŸè®¾è®¡äº†é¶å‘NAä¿æŠ¤è¡¨ä½çš„å¤šè‚½ç–«è‹— (Cell Rep, 2023)ï¼Œå¹¶ç»“åˆå…ˆè¿›çš„ç¯çŠ¶æ ¸é…¸ç–«è‹—å¹³å°ï¼Œå¼€å‘å‡ºæ–°å‹NAå¹¿è°±å…ç–«åŸã€‚è¯¥å…ç–«åŸåœ¨åŠ¨ç‰©æ¨¡å‹ä¸­æˆåŠŸè¯±å¯¼å‡ºå¼ºæ•ˆä¸”å¹¿è°±çš„ä¿æŠ¤æ€§å…ç–«åº”ç­”ï¼Œå±•ç°å‡ºè‰¯å¥½çš„è½¬åŒ–åº”ç”¨å‰æ™¯ (NPJ Vaccines, 2024)ã€‚</p><p>é’ˆå¯¹ç°æœ‰æ–°å† ç–«è‹—åœ¨é˜»æ–­ç—…æ¯’ä¼ æ’­ä¸Šçš„ä¸è¶³ï¼Œæˆ‘ä»¬<strong>åˆ©ç”¨ç­›é€‰åˆ°çš„å¹¿è°±é«˜æ•ˆä¸­å’ŒæŠ—ä½“ä¿¡æ¯ï¼Œåˆ›æ–°æ€§åœ°è®¾è®¡</strong>äº†åŸºäºä¸åŒ RBDä¸‰ç»´ç©ºé—´çš„ç»“æ„ç¨³å®šçš„ä¸‰èšä½“å¹¿è°±äººå·¥æ–°å† å…ç–«åŸã€‚è¯¥å…ç–«åŸå±•ç°å‡º<strong>ä¼˜å¼‚çš„ç¨³å®šæ€§</strong>ï¼Œå¹¶åœ¨åŠ¨ç‰©ä½“å†…æˆåŠŸ<strong>è¯±å¯¼å‡ºè¶…å¹¿è°±ã€å¼ºä¿æŠ¤æ€§çš„æŠ—ä½“åº”ç­”</strong> (Antiviral Res, 2025; Cell Mol Immunol, 2022)ã€‚<strong>ä¸ºçªç ´é»è†œå…ç–«å±éšœ</strong>ï¼Œæˆ‘ä»¬<strong>åˆ›æ–°æ€§åœ°é‡‡ç”¨é­æ¯›ç´ ä½å‰‚ç»“åˆæ»´é¼»å…ç–«ç­–ç•¥</strong>ï¼Œæœ‰æ•ˆ<strong>æ¿€æ´»äº†å…³é”®çš„é»è†œå…ç–«ï¼ˆç‰¹åˆ«æ˜¯IgAæŠ—ä½“ï¼‰å’Œç³»ç»Ÿå…ç–«åº”ç­”</strong>ã€‚æ”»æ¯’å®éªŒè¯æ˜ï¼Œè¯¥ç–«è‹—ç­–ç•¥<strong>èƒ½æœ‰æ•ˆä¿æŠ¤å°é¼ å¹¶æ˜¾è‘—å‡å°‘å‘¼å¸é“ç—…æ¯’è½½é‡</strong>ï¼Œ<strong>ä¸ºå¼€å‘èƒ½æœ‰æ•ˆé˜»æ–­ç—…æ¯’ä¼ æ’­çš„æ–°å† ç–«è‹—æä¾›äº†é‡è¦æ€è·¯å’Œå®éªŒä¾æ®</strong> (Signal Transduct Target Ther, 2023)ã€‚åŸºäºè¿™äº›æ‰å®çš„ä¸´åºŠå‰æ•°æ®ï¼Œæˆ‘ä»¬å›¢é˜Ÿ<strong>æ­£ä¸åˆä½œè€…åœ¨ä¸Šæµ·å…¬å…±å«ç”Ÿä¸´åºŠä¸­å¿ƒæ¨è¿›ç ”ç©¶è€…å‘èµ·çš„ä¸´åºŠè¯•éªŒ</strong>ï¼ŒåŠ é€Ÿå‘ä¸´åºŠè½¬åŒ–ã€‚</p><p>ä¸ºäº†æ›´ç²¾å‡†æŒ‡å¯¼ç–«è‹—è®¾è®¡ï¼Œæˆ‘ä»¬è¿ç”¨å•ç»†èƒæµ‹åºæŠ€æœ¯ï¼Œæ·±åº¦è§£æäº†ç—…æ¯’æ„ŸæŸ“å’Œç–«è‹—æ¥ç§åä¸åŒæ—¶é—´ç‚¹Bç»†èƒå…ç–«ç»„åº“çš„åŠ¨æ€å˜åŒ–å’Œå·®å¼‚ã€‚ç ”ç©¶å‘ç°ï¼Œè‡ªç„¶æ„ŸæŸ“èƒ½æ¿€æ´»æ›´å¤šæ ·åŒ–çš„Bç»†èƒå—ä½“ï¼ˆBCRï¼‰ï¼Œåˆ©ç”¨æ›´å¹¿æ³›çš„èƒšç³»åŸºå› ï¼ˆå¦‚VH3-33, VH4-31, VH1-69ç­‰ï¼‰ï¼›è€Œç–«è‹—æ¥ç§è¯±å¯¼çš„BCRå¤šæ ·æ€§ç›¸å¯¹å—é™ã€‚è¿™ä¸€é‡è¦å‘ç°æç¤ºï¼Œä¼˜åŒ–ç–«è‹—è®¾è®¡ï¼ˆç‰¹åˆ«æ˜¯åœ¨åˆæ¬¡å…ç–«é˜¶æ®µï¼‰åº”è‡´åŠ›äºæ¿€æ´»æ›´å¹¿æ³›çš„Bç»†èƒåº“ï¼Œä»è€Œè¯±å¯¼æ›´å¼ºã€æ›´å¹¿è°±çš„å…ç–«ä¿æŠ¤ (Emerg Microbes Infect, 2022)ã€‚</p><p>æˆ‘ä»¬çƒ­å¿±æ¬¢è¿å¯¹ä¼ æŸ“ç—…å…ç–«ã€ç–«è‹—ç ”å‘ã€AIä¸ç”Ÿç‰©åŒ»è¯äº¤å‰é¢†åŸŸå……æ»¡çƒ­æƒ…çš„ä¼˜ç§€å­¦å­åŠ å…¥ï¼Œä¹ŸæœŸå¾…ä¸å›½å†…å¤–åŒè¡Œå¼€å±•æ·±å…¥åˆä½œï¼Œå…±åŒåº”å¯¹å…¬å…±å«ç”ŸæŒ‘æˆ˜ã€‚</p><h4 id="ä¸»è¦æ‰¿æ‹…è¯¾é¢˜åŠäººæ‰é¡¹ç›®"><a href="#ä¸»è¦æ‰¿æ‹…è¯¾é¢˜åŠäººæ‰é¡¹ç›®" class="headerlink" title="ä¸»è¦æ‰¿æ‹…è¯¾é¢˜åŠäººæ‰é¡¹ç›®"></a>ä¸»è¦æ‰¿æ‹…è¯¾é¢˜åŠäººæ‰é¡¹ç›®</h4><p>å›½å®¶é’å¹´äººæ‰é¡¹ç›®åŸºé‡‘ï¼ˆ2021-2024ï¼‰ï¼Œåœ¨ç ”ï¼Œä¸»æŒ</p><p>æ·±åœ³å¸‚ç§‘æŠ€åˆ›æ–°å§”å‘˜ä¼šæ°å‡ºé’å¹´åŸºé‡‘ï¼ˆ2022-2027ï¼‰ï¼Œåœ¨ç ”ï¼Œä¸»æŒ</p><p>ç§‘æŠ€éƒ¨é‡ç‚¹ç ”å‘è®¡åˆ’ï¼ˆ2022-2025ï¼‰ï¼Œåœ¨ç ”ï¼Œè¯¾é¢˜è´Ÿè´£äºº</p><p>å›½å®¶è‡ªç„¶ç§‘å­¦åŸºé‡‘é‡å¤§ç ”ç©¶è®¡åˆ’ï¼ˆåŸ¹è‚²é¡¹ç›®ï¼‰ï¼ˆ2022-2024ï¼‰ï¼Œåœ¨ç ”ï¼Œä¸»æŒ</p><p>å›½å®¶è‡ªç„¶ç§‘å­¦åŸºé‡‘é¢ä¸Šé¡¹ç›®ï¼ˆ2020-2023ï¼‰ï¼Œåœ¨ç ”ï¼Œä¸»æŒ</p><p>æ·±åœ³å¸‚ç§‘æŠ€åˆ›æ–°å§”å‘˜ä¼šé‡ç‚¹ç ”å‘é¡¹ç›®ï¼ˆ2020-2023ï¼‰ï¼Œåœ¨ç ”ï¼Œæ ¸å¿ƒå‚ä¸</p><p>å¹¿ä¸œçœæ–°å† æŠ—ç–«é‡ç‚¹ç ”å‘é¡¹ç›®ï¼ˆ2021-2022ï¼‰ï¼Œç»“é¢˜ï¼Œä¸»æŒ</p><p>ä¸­å±±å¤§å­¦é’å¹´æ•™å¸ˆé‡ç‚¹åŸ¹è‚²è®¡åˆ’ï¼ˆ2019-2020ï¼‰ï¼Œç»“é¢˜ï¼Œä¸»æŒ</p><p>ä¸­å±±å¤§å­¦ç™¾äººè®¡åˆ’ä¸­é’å¹´æ°å‡ºäººæ‰ï¼ˆ2018-2020ï¼‰ï¼Œç»“é¢˜ï¼Œä¸»æŒ</p><h4 id="ä»£è¡¨æ€§ç§‘ç ”è®ºæ–‡"><a href="#ä»£è¡¨æ€§ç§‘ç ”è®ºæ–‡" class="headerlink" title="ä»£è¡¨æ€§ç§‘ç ”è®ºæ–‡"></a>ä»£è¡¨æ€§ç§‘ç ”è®ºæ–‡</h4><ol><li><p><strong>Chen YQ</strong>, Wohlbold TJ, Zheng NY, Huang M, Huang Y, Neu KE, Lee J, Wan H, Rojas KT, Kirkpatrick E, Henry C, Palm AE, Stamper CT, Lan LY, Topham DJ, Treanor J, Wrammert J, Ahmed R, Eichelberger MC, Georgiou G, Krammer F*, Wilson PC*. Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies. <strong><em>Cell</em></strong>. 2018 Apr 5;173(2):417-429.e10. <strong>(ç‹¬ç«‹ç¬¬ä¸€ä½œè€…ï¼Œä¸­ç§‘é™¢ä¸€åŒºï¼ŒIF=45.6)</strong></p></li><li><p>Kexin Lv#, Xiaoman Li#, Xingchen Zhu#, Jian-Piao Cai#, Shuning Liu#, Yuzhu Sun, Lin Liu, Xiaoyu Cai, Rui Cao, Mengxin Xu, Xinyu Yue, Yanmei Zhai, Wanyu Luo, Hongjie Lu, Ruiying Li, Haoting Mai, Lei Deng, Feng Ye, Shifeng Chen, Mang Shi, Huan-Le Luo, Xinquan Wang, Shuofeng Yuan*, Yue-Long Shu*, Jiwan Ge*, <strong>Yao-Qing Chen*</strong>.Broad Neuraminidase Antibodies Confer Protection Against Seasonal and Avian Influenza Viruses. <strong><em>Nature Communications</em></strong>. (Accept) <strong>(æœ€åé€šè®¯ä½œè€…ï¼Œä¸­ç§‘é™¢ä¸€åŒºï¼ŒIF=14.7)</strong></p></li><li><p>He B#, Liu S#, Wang Y#, Xu M, Cai W, Liu J, Bai W, Ye S, Ma Y, Hu H, Meng H, Sun T, Li Y, Luo H, Shi M, Du X, Zhao W, Chen S, Yang J, Zhu H, Jie Y, Yang Y, Guo D, Wang Q, Liu Y, Yan H, Wang M, Chen YQ*. Rapid isolation and immune profiling of SARS-CoV-2 specific memory B cell in convalescent COVID-19 patients via LIBRA-seq. Signal Transduction and Targeted Therapy. 2021 May 17;6(1):195. (ç‹¬ç«‹é€šè®¯ä½œè€…ï¼Œä¸­ç§‘é™¢ä¸€åŒºï¼ŒIF=40.8)*</p></li><li><p>Yang J#, Liu MQ#, Liu L#, Li X#, Xu M, Lin H, Li M, Yan H*, Chen YQ*, Shi ZL*. The protective nasal boosting of a triple-RBD subunit vaccine against SARS-CoV-2 following inactivated virus vaccination. Signal Transduction and Targeted Therapy. 2023 Apr 10;8(1):151.(å…±åŒé€šè®¯ä½œè€…ï¼Œä¸­ç§‘é™¢ä¸€åŒºï¼ŒIF=40.8)*</p></li><li><p>Li X#, Xu M#, Yang J#<em>, Zhou L, Liu L, Li M, Wang S, Liu MQ, Huang Z, Zhang Z, Liu S, Hu Y, Lin H, Liu B, Sun Y, Wu Q, Shi ZL, Lan K, Chen Y</em>, Yan H*, Chen YQ*. Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1. Signal Transduction and Targeted Therapy. 2024 Apr 27;9(1):114. (æœ€åé€šè®¯ä½œè€…ï¼Œä¸­ç§‘é™¢ä¸€åŒºï¼ŒIF=40.8)</p></li><li><p>Yang J#, Liu MQ#, Liu L#, Li X, Xu M, Lin H, Liu S, Hu Y, Li B, Liu B, Li M, Sun Y, Chen YQ*, Shi ZL*, Yan H*. A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concern. Cellular &amp; Molecular Immunology. 2022 Nov;19(11):1279-1289.(å…±åŒé€šè®¯ä½œè€…ï¼Œä¸­ç§‘é™¢ä¸€åŒºï¼ŒIF=21.8)*</p></li><li><p>Xu M#, Zhang Z#, Sun Y, Mai H, Liu S, Liu S, Lv K, Yu F, Wang Y, Yue X, Zhang J, Cai X, Zhao R, Lu H, Liu L, Luo H, Zhao H, Wang Y, Gong P, Chen S*, Jing X*, Zhao J*, Chen YQ*. IgA class switching enhances neutralizing potency against SARS-CoV-2 by increased antibody hinge flexibility. Antiviral Research. 2025 Mar;235:106082. Epub 2025 Jan 17. Erratum in: Antiviral Res. 2025 May;237:106146. (æœ€åé€šè®¯ä½œè€…ï¼Œä¸­ç§‘é™¢äºŒåŒºï¼ŒIF=4.5)</p></li><li><p>Yue X#, Zhong C#, Cao R#, Liu S#, Qin Z, Liu L, Zhai Y, Luo W, Lian Y, Zhang M, Lu H, Wang Y, Xu M, Liu S, Lv K, Sun Y, Zhu X, Mai H, Liao J, Yang J, Deng L, Liu Y, Sun C, Zheng KW*, Shu Y*, Chen YQ*. CircRNA based multivalent neuraminidase vaccine induces broad protection against influenza viruses in mice. NPJ Vaccines. 2024 Sep 16;9(1):170. (æœ€åé€šè®¯ä½œè€…ï¼Œä¸­ç§‘é™¢äºŒåŒºï¼ŒIF=7)*</p></li><li><p>Wang J#, Pan YF#, Yang LF#, Yang WH, Lv K, Luo CM, Wang J, Kuang GP, Wu WC, Gou QY, Xin GY, Li B, Luo HL, Chen S, Shu YL, Guo D, Gao ZH, Liang G, Li J, Chen YQ*, Holmes EC*, Feng Y*, Shi M*. Individual bat virome analysis reveals co-infection and spillover among bats and virus zoonotic potential. Nature Communications. 2023 Jul 10;14(1):4079.(å…±åŒé€šè®¯ä½œè€…ï¼Œä¸­ç§‘é™¢ä¸€åŒºï¼ŒIF=14.7)</p></li><li><p>Ma Y#, Li P#, Hu Y#, Qiu T, Wang L, Lu H, Lv K, Xu M, Zhuang J, Liu X, He S, He B, Liu S, Liu L, Wang Y, Yue X, Zhai Y, Luo W, Mai H, Kuang Y, Chen S, Ye F, Zhou N, Zhao W, Chen J, Chen S, Xiong X, Shi M, Pan JA*, Chen YQ*. Spike substitution T813S increases Sarbecovirus fusogenicity by enhancing the usage of TMPRSS2. PLoS Pathogens. 2023 May 17;19(5):e1011123.(æœ€åé€šè®¯ä½œè€…ï¼Œä¸­ç§‘é™¢ä¸€åŒºï¼ŒIF=5.5)</p></li><li><p>He B#, Liu S#, Xu M#, Hu Y, Lv K, Wang Y, Ma Y, Zhai Y, Yue X, Liu L, Lu H, Zhou S, Li P, Mai G, Huang X, Li C, Chen S, Ye S, Zhao P, Yang Y, Li X, Jie Y, Shi M, Yang J*, Shu Y*, Chen YQ*. Comparative global B cell receptor repertoire difference induced by SARS-CoV-2 infection or vaccination via single-cell V(D)J sequencing. Emerging Microbes &amp; Infections. 2022 Dec;11(1):2007-2020. (æœ€åé€šè®¯ä½œè€…ï¼Œä¸­ç§‘é™¢ä¸€åŒºï¼ŒIF=8.4)*</p></li><li><p>Meng H, Wang Y, Zhai Y, Luo W, Wang Y, Hu Y, Liu S, Xiao W, Yang G, Ye F, Chen S, Jie Y, Chen YQ. Unveiling the micronutrient-immunity puzzle in inactivated COVID-19 vaccination: A comprehensive analysis of circulating micronutrient levels and humoral responses in healthy adults. Journal of Medical Virology. 2024 Apr;96(4):e29611.(ç‹¬ç«‹é€šè®¯ä½œè€…ï¼Œä¸­ç§‘é™¢ä¸‰åŒºï¼ŒIF=6.8)</p></li><li><p>Chen Y, Lan L, Huang M, Henry C, Wilson P. Hemagglutinin stalk-reactive antibodies interfere with influenza virus neuraminidase activity by steric hindrance. Journal of Virology 93(4), 2019.(å°é¢æ–‡ç« )(ç‹¬ç«‹ç¬¬ä¸€ä½œè€…ï¼Œä¸­ç§‘é™¢äºŒåŒºï¼ŒIF=4)</p></li><li><p>Wang Y#, Hu Y#, Ma Y, Li P, Zhou S, Xu M, He B, Liu S, Lv K, Liu S, Zhang Y, Zhou N, Chen S, Ye F, Chen YQ. RBD class 1 and 2 antibody epitopes elicit around 70% neutralizing capacity against SARS-CoV-2 virus following boosting with inactivated virus vaccine. Vaccine. 2023 Dec 18;41(52):7641-7646.(ç‹¬ç«‹é€šè®¯ä½œè€…ï¼Œä¸­ç§‘é™¢ä¸‰åŒºï¼ŒIF=4.5)</p></li><li><p>Yu T#, Ling Q#, Xu M#, Wang N#, Wang L, Lin H, Cao M, Ma Y, Wang Y, Li K, Du L, Jin Y, Li Y, Guo D, Peng X*, Chen YQ*, Zhao B*, Pan JA*. ORF8 protein of SARS-CoV-2 reduces male fertility in mice. Journal of Medical Virology. 2022 Sep;94(9):4193-4205.(å…±åŒé€šè®¯ä½œè€…ï¼Œä¸­ç§‘é™¢ä¸‰åŒºï¼ŒIF=6.8)</p></li><li><p>Chen X#, Zheng L#, Ye S#, Xu M, Li Y, Lv K, Zhu H, Jie Y*, Chen YQ*. Research on Influencing Factors and Classification of Patients With Mild and Severe COVID-19 Symptoms. Frontiers in Cellular and Infection Microbiology. 2021 Aug 18;11:670823. (æœ€åé€šè®¯ä½œè€…ï¼Œä¸­ç§‘é™¢äºŒåŒºï¼ŒIF=4.6)</p></li><li><p>Zhao B, Zhong M, Yang Q, Hong K, Xia J, Li X, Liu Y, Chen YQ*, Yang J*, Huang C*, Yan H*. Alterations in Phenotypes and Responses of T Cells Within 6 Months of Recovery from COVID-19: A Cohort Study. Virologica Sinica, 2021;1-10.(å…±åŒé€šè®¯ä½œè€…ï¼Œä¸­ç§‘é™¢äºŒåŒºï¼ŒIF=4.3)</p></li><li><p>Chen Y#, Rajashankar KR#, Yang Y#, Agnihothram SS, Liu C, Lin YL, Baric RS, Li F. Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. Journal of Virology 87(19): 10777-10783, 2013.(ç¬¬ä¸€ä½œè€…ï¼Œä¸­ç§‘é™¢äºŒåŒºï¼ŒIF=4)</p></li></ol><h4 id="ä¸“åˆ©"><a href="#ä¸“åˆ©" class="headerlink" title="ä¸“åˆ©"></a>ä¸“åˆ©</h4><ol><li><strong>é™ˆè€€åº†</strong>ï¼Œç™½æ–‡å¨£ï¼Œææµ·ç²ï¼Œé©¬å‹‡ï¼›ä¸€ç§æŠ—ä½“ç»„åˆç‰©åŠå…¶åº”ç”¨ï¼›å›½å†…ä¸“åˆ©ï¼›ä¸“åˆ©å·ï¼šZL202110576276.4(å·²æˆæƒï¼Œ2022å¹´11æœˆ11æ—¥)ï¼›ä¸“åˆ©ç”³è¯·æ—¥ï¼š2021.05.26ï¼›æˆæƒå…¬å‘Šæ—¥ï¼š2022.11.11</li><li><strong>é™ˆè€€åº†</strong>ï¼Œä½•å…µï¼Œåˆ˜èˆ’å®ï¼Œç‹åª›åª›ï¼›æŠ—æ–°å‹å† çŠ¶ç—…æ¯’å—ä½“ç»“åˆåŒºåŸŸä¸­å’ŒæŠ—ä½“åŠå…¶åº”ç”¨ï¼›å›½å†…ä¸“åˆ©ï¼›ä¸“åˆ©å·ï¼šZL202110400882.0 (å·²æˆæƒï¼Œ2022å¹´9æœˆ20æ—¥)ï¼›ä¸“åˆ©ç”³è¯·æ—¥ï¼š2021.04.14ï¼›æˆæƒå…¬å‘Šæ—¥ï¼š2022.09.20</li><li><strong>é™ˆè€€åº†</strong>ï¼Œä½•å…µï¼Œåˆ˜èˆ’å®ï¼Œç‹åª›åª›ï¼Œå¾æ¢¦æ˜•ï¼Œé©¬å‹‡ï¼›æŠ—æ–°å‹å† çŠ¶ç—…æ¯’Nè›‹ç™½å•å…‹éš†æŠ—ä½“åŠå…¶åº”ç”¨ï¼›å›½å†…ä¸“åˆ©ï¼›ä¸“åˆ©å·ï¼šZL202110400892.4 (å·²æˆæƒï¼Œ2022å¹´9æœˆ22æ—¥)ï¼›ä¸“åˆ©ç”³è¯·æ—¥ï¼š2021.04.14ï¼›æˆæƒå…¬å‘Šæ—¥ï¼š2022.09.20</li><li><strong>é™ˆè€€åº†</strong>ï¼Œå¾æ¢¦æ˜•ï¼Œå•å¯æ­†ï¼Œåˆ˜èˆ’å®ï¼Œæœ±æ˜Ÿè¾°ï¼›æŠ—æ–°å‹å† çŠ¶ç—…æ¯’å—ä½“ç»“åˆåŒºåŸŸçš„ä¸­å’ŒæŠ—ä½“æˆ–å…¶æŠ—åŸç»“åˆç‰‡æ®µåŠå…¶åº”ç”¨ï¼›å›½å†…ä¸“åˆ©ï¼›ç”³è¯·å·ï¼šCN202411733088.8</li><li><strong>é™ˆè€€åº†</strong>ï¼Œç¿Ÿç‡•é•…ï¼Œç½—å©‰ç‰ï¼Œæè‰³ç²ï¼Œè”¡æ™“å®‡ï¼Œæ–½è½ï¼›ä¸€ç§æŠ—ä¹™å‹æµæ„Ÿè¡€å‡ç´ å•å…‹éš†æŠ—ä½“åŠå…¶åº”ç”¨ï¼›å›½å†…ä¸“åˆ©ï¼›ç”³è¯·å·ï¼šCN202410356131.7</li><li><strong>é™ˆè€€åº†</strong>ï¼Œèˆ’è·ƒé¾™ï¼Œæœ±æ˜Ÿè¾°ï¼Œå•å¯æ­†ï¼Œåˆ˜èˆ’å®ï¼Œå¾æ¢¦æ˜•ï¼Œå­™é›¨ç«¹ï¼Œå‘¨æ€ä¼Ÿï¼›æŠ—ç¥ç»æ°¨é…¸é…¶çš„å•å…‹éš†æŠ—ä½“åŠå…¶åº”ç”¨ï¼›å›½å†…ä¸“åˆ©ï¼›ç”³è¯·å·ï¼šCN202411217275.0</li><li><strong>é™ˆè€€åº†</strong>ï¼Œéƒ‘å…‹å¨ï¼Œå²³æ¬£ç…œï¼Œåˆ˜æ€å“²ï¼Œæ›¹è•Šï¼›ç¼–ç ç¥ç»æ°¨é…¸é…¶çš„ç¯çŠ¶RNAç»„åˆç‰©åŠå…¶åœ¨åˆ¶å¤‡æŠ—æµæ„Ÿç—…æ¯’çš„äº§å“ä¸­çš„åº”ç”¨ï¼›å›½å†…ä¸“åˆ©ï¼›ç”³è¯·å·ï¼šCN202410899915.4</li><li><strong>é™ˆè€€åº†</strong>ï¼Œéƒ‘å…‹å¨ï¼Œå•å¯æ­†ï¼›ä¸€ç§ç”¨äºSARS-CoV-2çš„å¯è§†åŒ–æ ¸é…¸æ£€æµ‹æ–¹æ³•åŠè¯•å‰‚ç›’ï¼›å›½å†…ä¸“åˆ©ï¼›ç”³è¯·å·ï¼šCN202210910452.8</li></ol>]]></content>
    
    
    <categories>
      
      <category>å®éªŒå®¤ä»‹ç»</category>
      
    </categories>
    
    
  </entry>
  
  
  
  <entry>
    <title>About ChenLab</title>
    <link href="/2025/06/18/About-ChenLab/"/>
    <url>/2025/06/18/About-ChenLab/</url>
    
    <content type="html"><![CDATA[<p>ChenLab æ˜¯ä¸­å±±å¤§å­¦å…¬å…±å«ç”Ÿå­¦é™¢ï¼ˆæ·±åœ³ï¼‰çš„äººå·¥æ™ºèƒ½ä¸ç–«è‹—ç ”ç©¶å®éªŒå®¤ï¼Œä¸“æ³¨äºä»¥ä¸‹ç ”ç©¶æ–¹å‘ï¼š</p><ul><li>ğŸ’¡ å¹¿è°±æµæ„Ÿç–«è‹—çš„ç ”å‘</li><li>ğŸ§  å¹¿è°±æ–°å† é»è†œç–«è‹—çš„ç ”å‘</li><li>ğŸ§¬ æ²»ç–—æ€§äººå•æŠ—çš„ç ”å‘å’Œä¸´åºŠåº”ç”¨ </li><li>ğŸ“ˆ Bç»†èƒå…ç–«åº”ç­”æœºåˆ¶åŠBCRå…ç–«ç»„åº“ç ”ç©¶</li></ul><p>æ¬¢è¿å…³æ³¨æˆ‘ä»¬çš„ç ”ç©¶è¿›å±•ï¼</p>]]></content>
    
    
    <categories>
      
      <category>å®éªŒå®¤ä»‹ç»</category>
      
    </categories>
    
    
    <tags>
      
      <tag>å®éªŒå®¤</tag>
      
      <tag>ç ”ç©¶æ–¹å‘</tag>
      
      <tag>å›¢é˜Ÿ</tag>
      
    </tags>
    
  </entry>
  
  
  
  <entry>
    <title>Hexo ä½¿ç”¨å¿ƒå¾—</title>
    <link href="/2025/06/17/hello-world/"/>
    <url>/2025/06/17/hello-world/</url>
    
    <content type="html"><![CDATA[<p>Welcome to <a href="https://hexo.io/">Hexo</a>! This is your very first post. Check <a href="https://hexo.io/docs/">documentation</a> for more info. If you get any problems when using Hexo, you can find the answer in <a href="https://hexo.io/docs/troubleshooting.html">troubleshooting</a> or you can ask me on <a href="https://github.com/hexojs/hexo/issues">GitHub</a>.</p><h2 id="å®‰è£…-Nodejs-å’Œ-Git"><a href="#å®‰è£…-Nodejs-å’Œ-Git" class="headerlink" title="å®‰è£… Nodejs å’Œ Git"></a>å®‰è£… Nodejs å’Œ Git</h2><h3 id="å®‰è£…Nodejs"><a href="#å®‰è£…Nodejs" class="headerlink" title="å®‰è£…Nodejs"></a>å®‰è£…Nodejs</h3><figure class="highlight python"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><code class="hljs python">hexo new <span class="hljs-string">&quot;My New Post&quot;</span><br></code></pre></td></tr></table></figure><p>More info: <a href="https://hexo.io/docs/writing.html">Writing</a></p><h3 id="å®‰è£…Git"><a href="#å®‰è£…Git" class="headerlink" title="å®‰è£…Git"></a>å®‰è£…Git</h3><figure class="highlight bash"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><code class="hljs bash">$ hexo server<br></code></pre></td></tr></table></figure><p>More info: <a href="https://hexo.io/docs/server.html">Server</a></p><h3 id="Generate-static-files"><a href="#Generate-static-files" class="headerlink" title="Generate static files"></a>Generate static files</h3><figure class="highlight bash"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><code class="hljs bash">$ hexo generate<br></code></pre></td></tr></table></figure><p>More info: <a href="https://hexo.io/docs/generating.html">Generating</a></p><h3 id="Deploy-to-remote-sites"><a href="#Deploy-to-remote-sites" class="headerlink" title="Deploy to remote sites"></a>Deploy to remote sites</h3><figure class="highlight bash"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><code class="hljs bash">$ hexo deploy<br></code></pre></td></tr></table></figure><p>More info: <a href="https://hexo.io/docs/one-command-deployment.html">Deployment</a></p><p>balabalabalabala</p>]]></content>
    
    
    
  </entry>
  
  
  
  
</search>
